![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea |
Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im |
Cancer Research and Treatment. 2017;49(2):454-463. Published online 2016 August 23 DOI: https://doi.org/10.4143/crt.2016.259 |
417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective 5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) PR86 RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective |
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014. |